CRISPR/Cas9 Gene Editing for CFTR Mutation Correction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Cystic Fibrosis (CF) and CF-like diseases do not reverse lung damage or cure the condition, leading to progressive respiratory failure and a limited average life expectancy of 37 years, with existing therapies only delaying disease progression and not addressing the underlying genetic mutations effectively.
Innovation Solution
The use of CRISPR/Cas-based methods to target and correct specific mutations in the CFTR gene and SCNN1A gene, aiming to restore CFTR channel function, reduce mucous viscosity, and inhibit ENaC overactivity through gene editing techniques such as homology-directed repair (HDR) and non-homologous end joining (NHEJ), potentially offering permanent correction with fewer doses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If current treatments are used to delay disease progression, then survival time is extended, but the underlying genetic mutation remains uncorrected and lung damage accumulates
Solution Approach 1:
The patent replaces conventional pharmacological treatments (mechanical/chemical approach) with CRISPR/Cas9 gene editing technology (biological molecular approach). The Cas9 endonuclease guided by gRNA specifically targets and cuts the mutated CFTR gene sequence, enabling precise genetic correction rather than symptomatic management. This substitution allows for potential curative effect by addressing the root genetic cause rather than merely delaying progression.
Solution Approach 2:
The patent introduces CRISPR/Cas9 components (Cas9 endonuclease and guide RNA) as intermediaries to achieve gene correction. These intermediaries facilitate targeted DNA cleavage and subsequent homology-directed repair using provided DNA templates, enabling precise correction of the F508del mutation without affecting other genes. This intermediary mechanism bridges the gap between therapeutic intent and genetic correction outcome.
2Reliability
If gene therapy approaches are used to deliver CFTR channel gene, then CFTR function is restored, but constant readministration is required due to high cell turnover
Solution Approach 1:
The patent performs preliminary correction of the CFTR gene mutation in epithelial cells before the cells undergo turnover. By using CRISPR/Cas9 to permanently edit the genome of resident stem or progenitor cells, the corrected gene is passed on to daughter cells during normal cell division. This preliminary genetic correction eliminates the need for repeated administrations, as the correction is heritable through cell division.
Solution Approach 2:
The patent utilizes the cell's own replication mechanism to copy the corrected CFTR gene to all progeny cells. Once the mutation is corrected in a stem or progenitor cell through CRISPR/Cas9 editing and homology-directed repair, every subsequent cell division automatically copies the corrected gene sequence, ensuring long-lasting expression of functional CFTR protein without requiring re-administration.
3Reliability
If CRISPR/Cas9 is used to correct CFTR mutation, then permanent correction is achieved, but delivery to lung epithelial cells must be efficient and specific
Solution Approach 1:
The patent employs local quality by designing delivery systems and CRISPR components that specifically target lung epithelial cells and airway surfaces. The guide RNA is designed to match the specific F508del mutation sequence in the CFTR gene, ensuring that editing occurs only at the intended location. Additionally, delivery vectors or formulations are optimized for lung tissue penetration and epithelial cell uptake, concentrating the therapeutic effect where it is needed without affecting other organs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach has the potential to permanently restore CFTR function and reduce ENaC overactivity, thereby ameliorating or curing lung, gastrointestinal, and reproductive symptoms of CF or CF-like disease, potentially improving life expectancy and quality of life by addressing the root cause of the condition.
Implementation Method 1
CRISPR/Cas-based methods to target and correct specific mutations in the CFTR gene and SCNN1A gene
Implementation Method 2
gene editing techniques such as homology-directed repair (HDR)
Implementation Method 3
non-homologous end joining (NHEJ)
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
CRISPR/CAS-related compositions and methods for treatment of Cystic Fibrosis (CF).